Mr. Supattanapong Punmeechaow, President and CEO of GC, and Professor Bundhit Eua-arporn, President of Chulalongkorn University, signed a memorandum of understanding (MoU) to initiate the feasibility study to develop innovation used in cellular immunotherapy. The goal is to enhance accessibility for Thais receiving cancer treatment and care on par with other advanced countries on June, 19 2019 at Customer Solution Center.

Mr. Supattanapong Punmeechaow said, “GC established the Corporate Venture Capital (CVC) division as a driving force behind the development of technology-based innovations that focus on four key industries: Advanced Materials, Digital Platforms, Clean Technology and Life Sciences. Our latest cooperation with Chulalongkorn University will result in a feasibility study to develop local medical innovations and technologies in Thailand. Initially, the study involves identifying guidelines and models in conducting cancer treatments using technologies for cellular immunotherapy treatments that will in turn, sustainably benefit the country’s social development. The feasibility study will also led to an investment plan that benefits cancer patients in Thailand by providing equal and affordable access to cancer care. This cooperation will further promote an important type of cancer treatment which can ultimately be included in public and private health insurance plans, and will build opportunities to deploy cellular immunotherapy in other ASEAN member countries, strengthening Thailand as a central medical hub.”